Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Market Cap	$376.03M	P/E Ratio	N/A
52W High	$6.55	52W Low	$0.73
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	82.0%
Overall Score	51	Value Score	40
Quality Score	31	Technical Score	83

EPS Current Est	$-0.49	EPS Next Est	$-0.44
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GALT	$5.50	+5.77%	306.07K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GALT	$5.50	+5.8%	306.07K
3
4
5
6

GALT

GALT

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Galectin Therapeutics Inc. Data in Excel

Get Galectin Therapeutics Inc. Data in Excel